N@N

Obagi Medical Products Introduces New Clinical Data Showing Combination of Hydroquinone Skin Care System and Tretinoin May Redu

^{Published on 2011-06-21 13:16:00 - Market Wire}
 

LONG BEACH, Calif.--([ BUSINESS WIRE ])--Obagi Medical Products, Inc. (Nasdaq: OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced the results from a new clinical study evaluating the efficacy of a hydroquinone skin care system (Nu-Derm®), plus tretinoin, in decreasing the severity of melasma, particularly in skin of color patients. This data was presented at the 22^nd World Congress of Dermatology (WCD) in May 2011.

"The results of this study clearly demonstrate that the combination of a 4% hydroquinone skin care system and 0.025% tretinoin is highly effective in reducing the severity and pigmentation intensity of melasma in those with darker skin"

aThe results of this study clearly demonstrate that the combination of a 4% hydroquinone skin care system and 0.025% tretinoin is highly effective in reducing the severity and pigmentation intensity of melasma in those with darker skin,a says Pearl Grimes, MD, co-lead investigator and Medical Director of the Vitiligo and Pigmentation Institute of Southern California. aMelasma is not merely a cosmetic nuisance, but a disorder that can cause emotional distress. I see it in my patients every day. I look forward to sharing this new information with my patients, as the treatment has also been shown to be well tolerated and to facilitate faster improvements in correcting photo-damaged skin.a

At the conclusion of the study, patients reported that the reduction in pigment discoloration actually decreased their self-consciousness by 60% and their feelings of overall unattractiveness by 45%. Moreover, 90% of patients reported that the treatment was more effective or much more effective than other medications they had used before.

Statistically significant benefits were seen in brown spots or discoloration, as well as in levels of skin texture and fine lines and wrinkles. Similarly, the exclusive treatment was clinically proven to increase patient satisfaction with 85% of patients being either Satisfied or Very Satisfied with the overall effectiveness.

aWith this new study we sought to evaluate the efficacy and tolerability of treating melasma in darker skin with a system containing two primary ingredients, hydroquinone and tretinoin, which have long been proven to be safe and effective,a said Dr. Grimes. aBy combining a 4% hydroquinone skin care system and a 0.025% tretinoin cream, we have revealed a specific regimen that not only treats melasma and delivers high levels of patient satisfaction, but one that offers a convenient skin care routine for those with darker skin.a

Study Methodology

The female participants in the clinical study ranged in age from 25 a" 65 years old. They all exhibited mild or moderate epidermal melasma and minimal to marked intensity of melasma pigmentation, as well as cutaneous melanosis that had been stable over the preceding three months. Over the course of the 12 week trial, 20 participants (13 African American and 7 Caucasian) completed the study.

About Obagi Medical Products, Inc.

Obagi Medical Products is a specialty pharmaceutical company that develops, markets and sells, and is a leading provider of, proprietary topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market. Using its Penetrating Therapeuticsa" technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, rosacea, and soft tissue deficits, such as fine lines and wrinkles. Obagi Medicala™s portfolio, which includes cosmetic, over-the-counter and prescription products, including 4% hydroquinone, is sold and promoted only through physician offices and requires education by a physician on proper use. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm®, Obagi-C® Rx (a prescription-strength vitamin C and hydroquinone system), Obagi® Professional-C (a line of highly stable vitamin C serums), Obagi Condition &Enhance® for use with cosmetic procedures to enhance patient outcomes and satisfaction, Obagi ELASTIderm® Eye Treatment and Obagi CLENZIderm® M.D. acne therapeutic systems, a formulation of Obagi CLENZIderm M.D. Systems for normal to dry skin, and Obagi ELASTIderm D©colletage System, Obagi Rosaclear® System, Obagi ELASTILasha" Eyelash Solution, Obagi Blue Peel RADIANCE^TM, and Nu-Derm® Sun Shield SPF 50. Visit [ www.obagi.com ] for information.

Blue Peel RADIANCE, ELASTIlash and Penetrating Therapeutics are trademarks, and Obagi, Blue Peel, Condition & Enhance, ELASTIderm, Nu-Derm, Obagi-C, Obagi CLENZIderm and Rosaclear are registered trademarks, of Obagi Medical Products, Inc. and/or its affiliates in the United States and certain other countries.